Bicorede Tablets 22400 IU (Cholecalciferol Concentrate Powder)

Adult dosage

Take 1 tablet (22,400 IU) orally with water every 28 days (4 weeks). Duration of treatment is based on the severity of the condition and the patient's response to treatment.

This medication should not be used in certain patients. Patients with allergic reactions to this drug or any of its ingredients, patients with vitamin D overdose, patients with kidney stones or nephrocalcinosis, and patients with hypercalcemia or hypercalciuria should not take this medication. Patients with severe renal impairment should also avoid using this medication. This drug contains lactose monohydrate, so patients with hereditary issues such as fructose intolerance, galactose intolerance, Lapp lactase deficiency, galactosemia, or glucose-galactose malabsorption should not take it. Patients with renal impairment or those undergoing treatment for cardiovascular disease, as well as those with a history of sarcoidosis or systemic inflammatory disease, should use this medication with caution. In particular, elderly patients or those prone to stone formation should regularly check serum calcium levels and renal function, and if abnormalities occur, the dosage should be reduced or discontinued. This drug can cause metabolic abnormalities such as hypercalcemia and hypercalciuria, and skin reactions like pruritus, rash, or urticaria may occur rarely. When taken for a long time, signs of hypercalcemia or renal impairment should be closely monitored. Patients with impaired renal function should periodically check their calcium and phosphate levels and consider the risk of soft tissue calcification due to the vitamin D content. In patients with specific illnesses such as sarcoidosis, vitamin D metabolism may increase, necessitating monitoring of calcium levels in blood and urine. When taking this medication with other vitamin D preparations, the total dosage should be adjusted accordingly, and the necessity of additional calcium supplementation should be determined based on a physician's instructions. Supervision by healthcare professionals is required during the treatment period to prevent hypercalcemia. This medication can interact with various substances including vitamin A, magnesium, antiepileptic drugs, rifampicin, cardiac glycosides, and corticosteroids. In particular, hypercalcemia can increase the toxicity of heart medications, so electrocardiograms and serum calcium levels should be closely monitored. Women who are pregnant should use this medication with caution, as it can affect the fetus and newborn; they must strictly follow their doctor's instructions. Nursing mothers should also carefully monitor for signs of vitamin D overdose in infants. This medication should not be administered to children, and routine checks of serum calcium levels are recommended for nursing infants. In the event of an overdose, symptoms such as arrhythmias, vomiting, dehydration, and kidney stones may occur due to hypercalcemia, so intake should be immediately stopped, and appropriate treatment should be sought. This medication should be stored out of the reach of children in a cool, dry place, avoiding direct sunlight and exposure to temperatures above 30 degrees Celsius. Furthermore, it should not be transferred to other containers to maintain quality.

Serious side effects

Urticaria, hypercalcemia, hypercalciuria, signs of hypercalcemia or renal impairment

Mild side effects

Itching, rash

This medication should be stored in a sealed container that blocks light, ideally at room temperature between 1 degree and 30 degrees Celsius. Storing it this way will help maintain the drug's effectiveness for a long time.

Appearance

White, convex rectangular film-coated tablet

Package unit

1 tablet_PTP/BOX, 3 tablets_PTP/BOX, 6 tablets_PTP/BOX